RESUMO
Objective:To explore the long-term effect of Zhenzhu Tiaozhi capsule（FTZ） on hemoglobin A1c（HbA1c）in patients with type 2 diabetes mellitus （T2DM） based on real-world data. Method:T2DM patients who were provided with FTZ （FTZ group） and those receiving conventional hypoglycemic drugs （control group） were extracted from the hospital information system （HIS） of the First Affiliated Hospital of Guangdong Pharmaceutical University， followed by propensity score matching （PSM） for balancing the confounding factors between groups. With HbA1c as the efficacy evaluation index， the difference in efficacy between the two groups was compared using <italic>t</italic>-test and <italic>χ</italic><sup>2</sup> test. For repeated measurement data of the same patient， the difference in efficacy and the stability of FTZ against HbA1c were analyzed by generalized estimating equation （GEE）. The factors that might affect the efficacy of FTZ against HbA1c were subjected to multivariate linear regression analysis （MLRA）， and the subgroup analyses were then conducted after the stratification of relevant factors. Result:There were 46 patients included in the FTZ group and 1 208 patients in the control group. PSM yielded 42 pairs of samples with balanced covariates between groups. As revealed by one-year observation， ① HbA1c in the FTZ group after treatment was 6.51%±1.09%. No significant difference was observed either in pre- and post-treatment comparison in the FTZ group or in its comparison with the control group. At the same time， the HbA1c compliance rate in the FTZ group was 73.8% after treatment. No significant difference was observed either in pre- and post-treatment comparison in the FTZ group or in its comparison with the control group. ② The GEE results showed that the post-treatment HbA1c levels in the two groups were not significantly different from each other. Moreover， the HbA1c level remained stable over treatment time. ③ MLRA and subgroup analyses results demonstrated that FTZ was more effective in patients with high baseline HbA1c ［<italic>β</italic>=-0.530，95% confidence interval（CI） -0.850～-0.209，<italic>P</italic><0.01］ or those who were complicated with hypertension （<italic>β</italic>=-0.918，95%CI -1.614～-0.222，<italic>P</italic><0.05）. Conclusion:In the real world， FTZ is able to control the blood sugar， and its effect is similar to those of conventional hypoglycemic drugs. Besides， it is capable of stabilizing the blood sugar for a long time.
RESUMO
<p><b>OBJECTIVE</b>To study the Chinese medicine (CM) syndrome typing of hyperlipidemia inpatients, thus exploring the CM syndrome typing laws.</p><p><b>METHODS</b>The clinical materials, including blood lipids, grading,complications, CM symptoms, and manifestations of tongue and pulse were recorded using self-formulated epidemiological questionnaire of CM syndrome in hyperlipidemia, and then these materials were statistically analyzed.</p><p><b>RESULTS</b>Gan-qi stagnation syndrome (66.46%) was the most often seen syndrome in the 316 hyperlipidemia inpatients. Gan stagnation Pi-deficiency syndrome (35.44%), Gan-Shen yin deficiency syndrome (16.77%), Pi-Shen yang deficiency syndrome (13.61%), inner stagnation of phlegm and stasis syndrome (13.29%), hyperactivity of yang and hypoactivity of yin syndrome (9. 18%) were 5 common syndromes of hyperlipidemia. Gan stagnation Pi-deficiency syndrome occupied an important position among all types and at various levels. Results from the lipid classification of hyperlipidemia showed that mixed type with low HDL-C was the most often seen (108/316, 34.18%), followed by mixed hyperlipidemia (81/316, 25.63%). Totally the mixing type accounted for 59.81% (189/316), higher than hypertriglyceridemia (16.77%) and hypercholesterolemia (23.42%).</p><p><b>CONCLUSIONS</b>Gan stagnation pi-deficiency syndrome might be the core syndrome affecting the lipid metabolism of hyperlipidemia. Mixed hyperlipidemia was the most often seen in clinics. Clinical medication should cover actions of decreasing TC and TG, and increasing HDL-C.</p>